A multi-tenant SaaS eQMS built 100% natively on Salesforce's Force.com platform, delivering pre-configured GxP processes (document control, CAPA, change control, training, audit, supplier, complaint, deviation, risk) with a vendor-supplied validation package, aimed at pharma, biotech, and medical-device quality and IT leaders who need to displace paper or fragmented systems quickly. Packaged tiers: eQMS Xpress (foundation), Compliance Xpand (cross-functional modules), Enterprise Xact (configurable enterprise), and the AI add-on AI Xpert / Dottie AI.
Dot Compliance Ltd. was founded in 2015 (vendor "About Us" page; Crunchbase records 2016), headquartered in Phoenix, Arizona with R&D in Israel. The company reports 201–500 employees on LinkedIn and "more than 500 customers across 30 countries." The product is listed on the Salesforce AppExchange as "#1 eQMS for Pharmaceutical & Medical Device Manufacturers."
The platform is positioned around three commercial pillars: (1) speed — vendor and AppExchange materials claim "go-live in days" for the Xpress edition and case studies describe deployments "within a few weeks"; (2) a vendor-delivered validation package covering 21 CFR Part 11 and EU Annex 11 — the vendor states "All of our solutions come with full validation packages"; and (3) embedded AI via Dottie AI (AI Xpert add-on), a generative and predictive AI assistant first released April 2023 and at its third major iteration as of January 2025, marketed for anomaly detection, regulatory-risk flagging, and vendor-agnostic decision guidance across multiple systems of record.
Dot Compliance is 100% native to Salesforce Force.com/Lightning. Customers do not need a separate Salesforce license — Salesforce capacity is bundled into the Dot Compliance subscription. Buyers inherit the Salesforce three-release-per-year cadence into their CSV calendar, and Salesforce platform pricing or AppExchange OEM term changes affect Dot Compliance economics.
Funding: $23M Series B (July 2022, led by Israel Growth Partners) and a $17.5M Series B extension (April 2024), totalling approximately $50M in disclosed funding. The company is investor-backed and growth-stage; at least one third-party reviewer described this as a continuity risk. By April 2024 the vendor reported surpassing 400 customers; the current "About Us" page states 500+ customers.
Deployment model: multi-tenant SaaS, 100% native on the Salesforce Force.com/Lightning platform. The vendor explicitly confirms customers do not need a separate Salesforce license — Salesforce capacity is bundled into the Dot Compliance subscription. The underlying Salesforce infrastructure runs on Salesforce's own data centres plus public-cloud regions (AWS/Hyperforce). Data-residency options are inherited from Salesforce regional infrastructure (US, EU, APAC regions, Hyperforce sovereign options); Dot Compliance does not publish a customer-facing data-residency menu. No on-premises deployment option.
Access: browser (Salesforce Lightning UI) plus native iOS and Android mobile apps (confirmed via GetApp; smartphone training completion and e-signature flows cited by users). SSO is provided via the Salesforce identity stack (SAML, OAuth/OIDC, Salesforce Identity, integration with Azure AD, Okta, Ping); specific IdP support is inherited from Salesforce platform capabilities rather than separately enumerated by Dot Compliance. API access is via Salesforce's REST/SOAP/Bulk/Streaming APIs and Platform Events — GetApp confirms "Dot Compliance has an API available for use." ERP integration (SAP, Oracle, NetSuite) and MES integration are described as "easy" through the native Salesforce platform. Specific pre-built connector inventory, rate limits, and SDK details are governed by Salesforce platform limits. Supported languages: English, French, German, Hebrew, Portuguese, Russian, Spanish. No published SLA uptime or transaction-throughput metric for the Dot Compliance application layer.
Pricing model: annual subscription, per-license, contact-for-pricing. The G2 pricing line reads "1 License Per Year — Contact us for pricing details." Tiered packaging — eQMS Xpress (foundation), Compliance Xpand (additional modules), Enterprise Xact (customizable), AI Xpert (AI add-on). No starting price is published on the vendor site, AppExchange listing, G2, Capterra, GetApp, or Software Advice; all routes funnel to a demo request. OpenRegulatory: "you'll only receive an offer after having scheduled a sales call... You can't self-start a free trial on the Dot Compliance website."
Multiple reviewers cite cost as a downside: "Because the QMS is built on the Salesforce platform, the licensing cost is often higher compared to some other standalone QMS options." Reported deal-size benchmarks: not published by vendor; industry analogs sit at $20K–$60K+ annually for small/mid teams; a mid-cap pharma multi-module enterprise deployment is conservatively estimated at $75K–$250K+ annually based on competitor benchmarks — Dot Compliance does not publicly confirm. Minimum contract length and setup fees are not publicly disclosed; industry norm in this category is 1–3 year minimums. A 14-day free trial (including full validation package and export-on-exit) was historically offered; whether this remains available without a sales call is unclear in current materials. Demo available via a qualification-gated "Get a demo" flow on the vendor website.
Vendor-claimed timeline: "go-live in days" for the Xpress edition (AppExchange datasheet). Case-study evidence: Unipharm and Scientia Clinical Research are described as weeks-scale deployments; Satsuma Pharmaceuticals (clinical-to-commercial transition) is months-scale without a published exact duration; Pi-Cardia completed ahead of a "critical U.S. launch" with no timeline quantified. For a mid-cap pharma rollout encompassing multi-site, multi-module deployment, a realistic timeline is 3–9 months or more, well past the vendor's "go-live in days" claim. One Capterra reviewer confirmed: "The implementation required time and internal effort, but once our processes were configured and users trained, the day-to-day work became more structured."
Services: vendor offers professional services (configuration, migration, validation assistance, training) with a dedicated Services page. Whether basic implementation is bundled in the subscription or separately priced as a statement of work is not publicly disclosed; reviewer commentary ("implementation costs can also be a barrier for smaller teams") suggests a separate professional-services SOW is standard. Migration: vendor hosts webinars on migrating from on-premises QMS to cloud. A 14-day free trial includes an export-at-termination commitment. Specific named migrators for legacy systems (TrackWise, Documentum, Veeva) are not advertised; standard Excel/CSV and Salesforce Data Loader ingestion are available from the Salesforce platform. Common pitfalls synthesized from reviews: (1) Salesforce learning curve for non-Salesforce shops; (2) multi-layer configuration ("multiple lifecycles within lifecycles") requiring admin support; (3) weak storage of validation documents inside Dot Compliance — many buyers need a parallel repository for V&V artifacts; (4) two-layer change management (Salesforce platform changes plus Dot Compliance application changes); (5) support response time was historically a concern (Israel-based support) — vendor states US-based support capacity has since expanded.
Anonymous feedback from pharmaceutical professionals using this solution
4.0 out of 5
Based on 95 verified reviews
Users consistently praise Dot Compliance for centralizing previously paper- or spreadsheet-based quality work into one connected system with traceable workflows. A Capterra reviewer summarized: "It clearly targets regulated environments, which gives us more confidence during inspections." Document management, training-to-document linkage (auto-triggered retraining on SOP revision), and the audit trail draw the most positive sentiment. One Capterra reviewer wrote: "The product is user friendly. The flows in the system are the best practices that are used in the pharmaceutical industry (21 CFR Part 11, Annex 11, GAMP 5). Almost no adjustments (customizations) are needed. The validation package is very thorough and comprehensive." Customer support is generally well-reviewed since the vendor expanded its North America team. The Salesforce foundation is repeatedly cited as a familiarity and integration advantage for organizations already running Salesforce CRM or Service Cloud.
The most consistent complaints cluster around five areas: (1) Cost — "Because the QMS is built on the Salesforce platform, the licensing cost is often higher compared to some other standalone QMS options"; implementation costs are also flagged as "a barrier for smaller teams." (2) UI density and navigation complexity — "Some screens feel a bit crowded and could be more intuitive for occasional users"; "the system contains multiple lifecycles within lifecycles, which makes navigation a little bit confusing." (3) Two-layer change management burden — "you have to deal with both changes to Dot Compliance and Salesforce," i.e., the buyer's CSV team must track and revalidate against both Salesforce's three-per-year release cadence and Dot Compliance application upgrades. (4) Module-level limitations — the auditing module is called out as needing improvement in permissions and licensing granularity; the OOTB CAPA template's root-cause section is flagged as weak; printing workflows and form output are reportedly clunky. (5) Weak validation-document repository — "Dot Compliance is very specific to the intended use of an eQMS (not great for storing validation documents)," meaning buyers often need a separate parallel system for V&V artifacts.
Share your experience with Dot Compliance QMS anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section